The Galien Forum USA 2019

PANEL
4

Co-Chairs
Susan Desmond-Hellmann
Chief Executive Officer
Bill & Melinda Gates Foundation
Prix Galien USA Committee Chair

Mike Rosenblatt
Chief Medical Officer
Flagship Pioneering

Panelists
Albert Bourla
Chief Executive Officer
Pfizer

Jacqualyn Fouse
Chief Executive Officer
Agios

Christophe Weber
Chief Executive Officer
Takeda

Panel Intro

How will we be paying for medicine 10 years from now? (CEO panel)


Co-Chair
Susan Desmond-Hellmann
Chief Executive Officer
Bill & Melinda Gates Foundation
Prix Galien USA Committee Chair

Sue Desmond-Hellmann, MD, MPH, is CEO of the Bill & Melinda Gates Foundation. Trained as an oncologist, she previously spent 14 years at Genentech developing a number of breakthrough medicines, including two of the first gene-targeted therapies for cancer, Avastin and Herceptin. In November 2009, Forbes named her one of the world’s seven most “powerful innovators,” calling her “a hero to legions of cancer patients.” In her current role she champions a similar approach to global development: precision public health – getting the right interventions, to the right populations, in the right places, to save lives. Sue was also the first female chancellor of the University of California at San Francisco (UCSF), overseeing all aspects of the university and medical center’s strategy and operations. Sue is the recipient of numerous honors and awards and was listed among Fortune magazine’s “top 50 most powerful women in business” for seven years. In 2010, she was inducted into the American Academy of Arts and Sciences and elected to the Institute of Medicine. She is a director at Facebook Inc.


Mike_OhanaCo-Chair
Mike Rosenblatt

Chief Medical Officer
Flagship Pioneering

Dr. Rosenblatt’s career has been in academia, pharma and biotech/venture. he is a physician—scientist. he now serves as Chief Medical Officer of Flagship Pioneering in Cambridge, MA, a firm that originates new biotech companies. Previously, he was Merck’s first Chief Medical Officer. he also served as Dean of Tufts University School of Medicine, and before that, Robert Ebert Professor of Molecular Medicine and George R. Minot Professor at Harvard Medical School. he served as President of Beth Israel Deaconess Medical Center and Director of the Harvard-MIT Division of health Sciences and Technology.

At Merck, he co-led development of alendronate (FOSAMAX) for osteoporosis. he received the Fuller Albright Award, the Vincent du Vigneaud Award, and the Chairman’s Award from Merck. Active in biotechnology, he was a founder of ProScript, which discovered bortezomib (Velcade) for multiple myeloma, and Radius, which developed abaloparatide (Tymlos) for osteoporosis. Currently, he is a member of the Harvard Medical School Board of Fellows, and the research advisory committees of Massachusetts General, Brigham and Women’s, and Boston Children’s hospitals. he graduated summa cum laude from Columbia, and received his M.D. magna cum laude from Harvard. Internship, residency, and endocrinology training were all at Massachusetts General hospital.

Albert Bourla
Chief Executive Officer
Pfizer


Jacqualyn Fouse
Chief Executive Officer
Agios


Christophe Weber
Chief Executive Officer
Takeda